Goldman Sachs’s ARK Genomic Revolution ETF ARKG Stock Holding History

Goldman Sachs’s Portfolio ARKG Stock Details ARKG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-50,000	Closed	-$1.41M	–	5901
2022 Q4	$1.41M	Hold	50,000	–	–	﹤0.01%	4191
2022 Q3	$1.64M	Sell	50,000 -35,000	-41%	-$1.28M	﹤0.01%	4139
2022 Q2	$2.68M	Sell	85,000 -367,900	-81%	-$12.9M	﹤0.01%	3784
2022 Q1	$20.8M	Buy	452,900 +90,800	+25%	+$4.33M	﹤0.01%	2017
2021 Q4	$22.2M	Buy	362,100 +312,100	+624%	+$21.6M	﹤0.01%	2026
2021 Q3	$3.74M	Sell	50,000 -386,400	-89%	-$32.4M	﹤0.01%	3603
2021 Q2	$40.4M	Buy	+436,400	New	+$37.1M	0.01%	1444

Other funds holding ARKG

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

State of Wisconsin Investment Board Madison, Wisconsin $43.7B AUM 27.76% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

Goldman Sachs's ARKG Position: Q1 2026 in Review

Goldman Sachs increased its ARK Genomic Revolution ETF (ARKG) stake by 43% in Q1 2026, buying an estimated $25M and bringing the position to 2,857,394 shares worth $75.5M. The position accounts for 0.01% of the portfolio, ranked #1246.

Goldman Sachs first reported a position in ARKG in Q4 2020 and has held it in 22 quarters since. The position peaked at $85.4M in Q4 2024. 218 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

Goldman Sachs held 2,857,394 shares of ARK Genomic Revolution ETF worth $75.5M as of Q1 2026.
Goldman Sachs bought 853,530 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $25M.
ARK Genomic Revolution ETF made up 0.01% of Goldman Sachs's portfolio in Q1 2026, its #1246 holding.
Goldman Sachs first reported a position in ARK Genomic Revolution ETF in Q4 2020 and has held it in 22 quarters since.
Goldman Sachs's ARK Genomic Revolution ETF position peaked at $85.4M in Q4 2024.
218 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.